Loading...
RGD-Binding Integrins in Head and Neck Cancers
Ahmedah, H.T. Patterson, Laurence H. Sheldrake, Helen M.
Ahmedah, H.T.
Patterson, Laurence H.
Sheldrake, Helen M.
Publication Date
26/05/2017
End of Embargo
Supervisor
Rights
© 2017 The Authors. This is an open access article distributed under
the Creative Commons CC-BY license (https://creativecommons.org/licenses/by/4.0/) which
permits unrestricted use, distribution, and reproduction in any medium, provided the original
work is properly cited.
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
23/05/2017
Institution
Department
Awarded
Embargo end date
Collections
Abstract
Alterations in integrin expression and function promote tumour growth, invasion, metastasis and neoangiogenesis. Head and neck cancers are highly vascular tumours with a tendency to metastasise. They express a wide range of integrin receptors. Expression of the αv and β1 subunits has been explored relatively extensively and linked to tumour progression and metastasis. Individual receptors αvβ3 and αvβ5 have proved popular targets for diagnostic and therapeutic agents but lesser studied receptors, such as αvβ6, αvβ8, and β1 subfamily members, also show promise. This review presents the current knowledge of integrin expression and function in squamous cell carcinoma of the head and neck (HNSCC), with a particular focus on the RGD-binding integrins, in order to highlight the potential of integrins as targets for personalised tumour specific identification and therapy.
Version
Published version
Citation
Ahmedah HT, Patterson LH, Shnyder SD et al (2017) RGD-Binding Integrins in Head and Neck Cancers. Cancers. 9(6). 56.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article